Pharmaceutical - Cardio-vascular, Markets & Marketing

Filter

Popular Filters

1 to 25 of 53 results

AstraZeneca to pay $7.9 million to resolve kickback allegations in USA

AstraZeneca to pay $7.9 million to resolve kickback allegations in USA

12-02-2015

Anglo-Swedish pharma major AstraZeneca has agreed to pay the US government $7.9 million to settle allegations…

AstraZenecaCardio-vascularGastro-intestinalsLegalMarkets & MarketingNexiumPharmaceuticalPlendilPrilosecToprol XLUSA

Biologics will complement statins in cholesterol treatment space, says GlobalData

Biologics will complement statins in cholesterol treatment space, says GlobalData

11-11-2014

Biologics will play an influential role in shaping the future of cardiovascular drug treatment, in particular…

alirocumabAmgenCardio-vascularevolocumabMarkets & MarketingPharmaceuticalRegeneronSanofiUSA

ScinoPharm and Nanjing King-friend team up to market new drugs in China

ScinoPharm and Nanjing King-friend team up to market new drugs in China

10-11-2014

ScinoPharm Taiwan and China’s Nanjing King-friend Biochemical Pharmaceutical (NKF) announced today…

Cardio-vascularChinaMarkets & MarketingNanjing King-friend BiochemicalPharmaceuticalRegadenoson InjectionResearchScinoPharma Taiwan

Pharming and Salix's Ruconest launches in the USA for hereditary angioedema

Pharming and Salix's Ruconest launches in the USA for hereditary angioedema

03-11-2014

Pharming Group and Salix Pharmaceuticals have launched Ruconest (C1 esterase inhibitor) in the USA for…

Cardio-vascularMarkets & MarketingPharmaceuticalPharming Group NVRuconestSalixUSA

Acute coronary syndrome treatment market to more than triple by 2023

Acute coronary syndrome treatment market to more than triple by 2023

30-07-2014

The launch of several drugs with “extraordinary blockbuster potential” will cause the acute coronary…

Acute coronary syndromealirocumabAmgenBayerCardio-vascularEuropeevolocumabJapanMarkets & MarketingMerck & CoPfizerPharmaceuticalSanofiUSAXareltoZontivity

Brazil and Mexico physicians’ preferences on anticoagulants

25-07-2014

Novel oral anticoagulants (NOACs) such as Bayer’s Xarelto (rivaroxaban), Boehringer Ingelheim’s Pradaxa…

BayerBoehringer IngelheimBrazilBristol-Myers SquibbCardio-vascularEliquisMarkets & MarketingMexicoPfizerPharmaceuticalPradaxaPricingXarelto

Third-party investigation confirms Takeda’s systematic involvement in CASE-J Study, but no data tampering

Third-party investigation confirms Takeda’s systematic involvement in CASE-J Study, but no data tampering

23-06-2014

Japan’s largest drugmaker Takeda Pharmaceuticals has updated on the third-party surrounding the results…

BlopressCardio-vascularJapanMarkets & MarketingPharmaceuticalResearchTakeda Pharmaceutical

China cardiovascular drugs market set to grow to 45 billion renminbi by 2018

China cardiovascular drugs market set to grow to 45 billion renminbi by 2018

13-06-2014

A new report titled Research on China Cardiovascular Drugs Industry 2014-2018, says that, in the next…

Cardio-vascularChinaMarkets & MarketingPharmaceutical

High price of novel antithrombotics a major deterrent to patient access in China

High price of novel antithrombotics a major deterrent to patient access in China

10-06-2014

The high cost of therapy remains a significant barrier for uptake of novel oral anticoagulants (NOACs)…

BayerBoehringer IngelheimBristol-Myers SquibbCardio-vascularChinaEliquisMarkets & MarketingPharmaceuticalPradaxaPricingWarfarin SodiumXarelto

Global anti-hypertensives market will see decline as key patents expire

Global anti-hypertensives market will see decline as key patents expire

04-06-2014

Multiple major drug patent expiries will cause the global anti-hypertensive drug market value to decline…

Cardio-vascularMarkets & MarketingPharmaceuticalResearch

Daiichi Sankyo launches blood thinner Efient in Japan

27-05-2014

Daiichi Sankyo said this morning that it has launched its anti-blood clotting drug Efient (prasugrel…

Cardio-vascularDaiichi SankyoEfientJapanMarkets & MarketingPharmaceuticalRegulation

Gilead’s Sovaldi set to claim Humira’s crown as top-selling drug in 2020

Gilead’s Sovaldi set to claim Humira’s crown as top-selling drug in 2020

02-05-2014

Having achieved the biggest drug launch to date by generating an astonishing $2.3 billion in its first…

AbbVieAnti-viralsBayerBristol-Myers SquibbCardio-vascularDiabetesGilead SciencesHumiraJanuviaLantusMarkets & MarketingMerck & ConivolumabPharmaceuticalSanofiSovaldiXarelto

JPMA sanctions against Takeda over promotional activities for candesartan in Japan

09-04-2014

Japan’s largest drugmaker Takeda Pharmaceutical says it has received notice of sanctions imposed by…

Asia-PacificBlopressCardio-vascularJapanMarkets & MarketingPharmaceuticalTakeda Pharmaceuticals

ACCC acts on Pfizer’s alleged anti-competitive conduct in Australia

ACCC acts on Pfizer’s alleged anti-competitive conduct in Australia

13-02-2014

The Australian Competition and Consumer Commission revealed today that is has instituted proceedings…

Asia-PacificAustraliaCardio-vascularLegalLipitorMarkets & MarketingPfizerPharmaceutical

Japan to investigate Novartis promotion of Diovan; US allegation over Exjade

Japan to investigate Novartis promotion of Diovan; US allegation over Exjade

10-01-2014

Swiss drug major Novartis faced two problems yesterday, when the Japanese Ministry of Health Labor and…

Asia-PacificCardio-vascularDiovanExjadeHematologyLegalMarkets & MarketingNorth AmericaNovartisPharmaceuticalUSA

Atherothrombotic diseases market to grow to $47 billion in 2022

Atherothrombotic diseases market to grow to $47 billion in 2022

23-12-2013

The launch of numerous add-on therapies in the atherothrombotic diseases market (incorporating pharmacotherapies…

AstraZenecaBayerBrilintaCardio-vascularEli LillyevacetrapibGlobalMarkets & MarketingPharmaceuticalXarelto

Novel oral anticoagulants will continue to drive atrial fibrillation drug market growth

20-12-2013

The atrial fibrillation drug market will experience continued growth through the rest of the decade,…

Asia-PacificBayerBoehringer IngelheimBristol-Myers SquibbCardio-vascularEliquisEuropeMarkets & MarketingNorth AmericaPfizerPharmaceuticalPradaxaXarelto

Modest growth forecast for global CD market

02-12-2013

The global market for cardiovascular disease - comprised of heart failure, myocardial infarction and…

AstraZenecaAZD6140BAY81-8781BayerCardio-vascularLCZ696Markets & MarketingNovartisPharmaceuticalPricingserelaxin

Case study draws attention to innovator brand preferences in Kenya

08-10-2013

Some of the stronger performing brands in Kenya’s pharmaceutical market have been highlighted in a…

Antibiotics and Infectious diseasesCardio-vascularDiabetesGlaxoSmithKlineMarkets & MarketingPharmaceuticalRest of the World

Bayer/Janssen's Xarelto poised to lead sales in VTE market: report

30-08-2013

German drug major Bayer (BAYN: DE) and Johnson & Johnson (NYSE: JNJ) subsidiary Janssen's Xarelto (rivaroxaban)…

BayerBristol-Myers SquibbCardio-vascularEliquisGlobalJanssenJohnson & JohnsonMarkets & MarketingPfizerPharmaceuticalXarelto

Radiopharmaceuticals market to hit a value of $7.9 billion by 2018

21-08-2013

The radiopharmaceuticals market has been forecast to exceed a value of $7.9 billion by 2018, driven by…

Cardio-vascularGlobalMarkets & MarketingNeurologicalOncologyPharmaceutical

Akrikhin expands deal with Merck & Co

08-08-2013

Leading Russian drugmaker Akrikhin says it has expanded its partnership with US pharma giant Merck &…

Akrikhin PharmaceuticalsCardio-vascularDiabetesEuropeEzetrolJanumetJanuviaMarkets & MarketingMerck & CoNoxafilPharmaceuticalProductionRespiratory and PulmonarySingulair

Novartis's new heart failure drug to dominate with $1.9 billion global revenue by 2022, says GlobalData

21-06-2013

Following a launch scheduled for 2015 for the treatment of chronic heart failure (CHF), Swiss drug major…

Cardio-vascularLCZ-696Markets & MarketingNovartisPharmaceutical

1 to 25 of 53 results

COMPANY SPOTLIGHT

Menarini

Back to top